There have been stunning “firsts” in research on idiopathic pulmonary fibrosis (IPF), a mysterious disease that stiffens and stills the lungs, killing half its victims in three years. In May, results of Phase 3 clinical trials on the first two effective drugs for IPF were published in the New England Journal of Medicine (NEJM). And in June, the first paper explaining IPF was published in Science Translational Medicine.
A large-scale University-led study involving more than 180,000 people shows that patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition. The findings indicate that a drug known as metformin, used to control glucose levels in the body and already known to exhibit anticancer properties, could offer prognostic and prophylactic benefits to people without diabetes.
In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers report that they have identified a possible new drug target for treating the disease.
University of Washington bioengineers have discovered a potentially faster way to deliver a topical drug that protects women from contracting HIV. Their method spins the drug into silk-like fibers that quickly dissolve when in contact with moisture, releasing higher doses of the drug than possible with other topical materials such as gels or creams.
On this episode of Bioscience Technology This Week, Editor-in-Chief Rob Fee reports on gold nanoparticles' promise in drug delivery. Our second story examines the work being done to decipher the wheat genome and the implications of this work.
Microorganisms can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. Now, a new study has shown that microorganisms can use a temporary silencing of drug targets to gain the benefits of drug resistance without the commitment.
Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers.
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.
A daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease. Now, a new study suggests that common genetic variation may modify the cardiovascular benefit of aspirin.
Scientists may be able to entomb the malaria parasite in a prison of its own making, researchers at are reporting. The malaria parasite is among the world’s deadliest pathogens.
Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate.
Researchers have moved one step closer to a gene therapy that could silence the faulty SOD1 gene responsible for triggering a form of motor neuron disease also known as amyotrophic lateral sclerosis (ALS).
A Mississippi girl born with the AIDS virus and in remission for years despite stopping treatment now shows signs that she still harbors HIV — and therefore is not cured.
It may smell awful and have a reputation for being highly toxic, but when used in the right tiny dosage, hydrogen sulfide is now being found to offer potential health benefits in a range of issues, from diabetes to stroke, heart attacks and dementia.
Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics—and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids. Their study found the nanopyramids can flag bacteria and kill more of them than medicine alone.
An AIDS research team at Iowa State University will not get the final $1.38 million payment of a National Institutes of Health five-year grant after a team member admitted last year to faking research results.
A few therapies derived from human medicine are available for dogs, but a very successful form of therapy by which antibodies inhibit tumor growth has not yet been available for animals. Now, scientists have developed, for the first time, antibodies to treat cancer in dogs.
A team of researchers has shown for the first time that stem cells created using different methods produce differing cells. The findings provide new insights into the basic biology of stem cells and could ultimately lead to improved therapies.
A new study by radiation oncologists has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT in a variety of advanced head and neck cancers.
New experiments have identified a compound that might halt the progression of Alzheimer’s by interfering with the role amyloid-beta plays in the formation of blood clots.
Supercomputer simulations have shown that clusters of a protein linked to cancer warp cell membranes, according to scientists at The University of Texas Health Science Center at Houston (UTHealth) Medical School. This research on these protein clusters, or aggregates as scientists call them, could help guide design of new anticancer drugs.
By scouring the DNA of thousands of patients, researchers have discovered four rare gene mutations that not only lower the levels of triglycerides, a type of fat in the blood, but also significantly reduce a person’s risk of coronary heart disease—dropping it by 40 percent. The mutations all cripple the same gene, called APOC3, suggesting a powerful strategy in developing new drugs against heart disease.
Computer simulations that reveal a key mechanism in the replication process of influenza A may help defend against future deadly pandemics. Treating influenza relies on drugs, such as Amantadine, that are becoming less effective due to viral evolution. But University of Chicago scientists have published computational results that may give drug designers the insight they need to develop the next generation of effective influenza treatment.
Everyone loves a grand slam: the crack of the bat, the arc of the ball as it sails over the fence, a tip of the batter’s cap, a triumphal trot around as the bases empty out, but really, it’s the lesser efforts that made it all possible—a double, a single, a walk—it’s the incremental gains that win the game. It’s called Small Ball. This year’s ASCO, absent the heavy hitters, was all about the small ball.
A new drug target to fight Alzheimer's disease has been discovered by a research team led by Gong Chen, a professor of biology and the Verne M. Willaman Chair in Life Sciences at Penn State. The discovery also has potential for development as a novel diagnostic tool for Alzheimer's disease.